{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:15:15Z","timestamp":1790882115223,"version":"4.1.0"},"reference-count":82,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,6,14]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this systematic review was to assess the efficacy and safety of pharmacological agents in the management of agitated behaviours following traumatic brain injury (TBI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a search strategy in PubMed, OvidMEDLINE, Embase, CINAHL, PsycINFO, Cochrane Library, Google Scholar, Directory of Open Access Journals, LILACS, Web of Science and Prospero (up to 10 December 2018) for published and unpublished evidence on the risks and benefits of 9 prespecified medications classes used to control agitated behaviours following TBI. We included all randomised controlled trials, quasi-experimental and observational studies examining the effects of medications administered to control agitated behaviours in TBI patients. Included studies were classified into three mutually exclusive categories: (1) agitated behaviour was the presenting symptom; (2) agitated behaviour was not the presenting symptom, but was measured as an outcome variable; and (3) safety of pharmacological interventions administered to control agitated behaviours was measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 181 articles assessed for eligibility, 21 studies were included. Of the studies suggesting possible benefits, propranolol reduced maximum intensities of agitation per week and physical restraint use, methylphenidate improved anger measures following 6 weeks of treatment, valproic acid reduced weekly agitated behaviour scale ratings and olanzapine reduced irritability, aggressiveness and insomnia between weeks 1 and 3 of treatment. Amantadine showed variable effects and may increase the risk of agitation in the critically ill. In three studies evaluating safety outcomes, antipsychotics were associated with an increased duration of post-traumatic amnesia (PTA) in unadjusted analyses. Small sample sizes, heterogeneity and an unclear risk of bias were limits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Propranolol, methylphenidate, valproic acid and olanzapine may offer some benefit; however, they need to be further studied. Antipsychotics may increase the length of PTA. More studies on tailored interventions and continuous evaluation of safety and efficacy throughout acute, rehabilitation and outpatient settings are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42016033140<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-029604","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T12:25:47Z","timestamp":1562675147000},"page":"e029604","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":85,"title":["Pharmacological interventions for agitated behaviours in patients with traumatic brain injury: a systematic review"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03095066","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01322048","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David","family":"Williamson","sequence":"first","affiliation":[{"name":"Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Pharmacy, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Julie","family":"Frenette","sequence":"additional","affiliation":[{"name":"Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D","family":"Burry","sequence":"additional","affiliation":[{"name":"Pharmacy, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"Faculty of Pharmacy, University of Toronto Leslie Dan, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Perreault","sequence":"additional","affiliation":[{"name":"Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Pharmacy, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Charbonney","sequence":"additional","affiliation":[{"name":"M\u00e9decine, Universit\u00e9 de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Lamontagne","sequence":"additional","affiliation":[{"name":"Medecine, Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Julie","family":"Potvin","sequence":"additional","affiliation":[{"name":"Psychology, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Gigu\u00e8re","sequence":"additional","affiliation":[{"name":"Neurosurgery, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"M\u00e9decine, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Bernard","sequence":"additional","affiliation":[{"name":"M\u00e9decine, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Critical Care, Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"key":"2025120619031013000_9.7.e029604.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature16035"},{"key":"2025120619031013000_9.7.e029604.2","doi-asserted-by":"publisher","DOI":"10.1097\/HTR.0b013e3181ccc8b4"},{"key":"2025120619031013000_9.7.e029604.3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2377-12-76","article-title":"Direct cost associated with acquired brain injury in Ontario","volume":"12","author":"Chen","year":"2012","journal-title":"BMC Neurol"},{"key":"2025120619031013000_9.7.e029604.4","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3109\/02699052.2012.722256","article-title":"Treatment costs and productivity losses caused by traumatic brain injuries","volume":"26","author":"Tuominen","year":"2012","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.5","doi-asserted-by":"publisher","DOI":"10.1097\/HTR.0b013e3181dedd0e"},{"key":"2025120619031013000_9.7.e029604.6","doi-asserted-by":"publisher","DOI":"10.1080\/026990500421895"},{"key":"2025120619031013000_9.7.e029604.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9993(96)90306-8"},{"key":"2025120619031013000_9.7.e029604.8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.PHM.0000140790.30468.F4","article-title":"Gender Differences in Agitation After Traumatic Brain Injury","volume":"83","author":"Kadyan","year":"2004","journal-title":"Am J Phys Med Rehabil"},{"key":"2025120619031013000_9.7.e029604.9","doi-asserted-by":"publisher","DOI":"10.1080\/02699050600832684"},{"key":"2025120619031013000_9.7.e029604.10","doi-asserted-by":"publisher","DOI":"10.3109\/02699052.2013.873142"},{"key":"2025120619031013000_9.7.e029604.11","doi-asserted-by":"publisher","DOI":"10.1080\/02699050601049114"},{"key":"2025120619031013000_9.7.e029604.12","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-200109000-00002"},{"key":"2025120619031013000_9.7.e029604.13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/rnj.82","article-title":"Occurrence and severity of agitated behavior after severe traumatic brain injury","volume":"38","author":"Wolffbrandt","year":"2013","journal-title":"Rehabil Nurs"},{"key":"2025120619031013000_9.7.e029604.14","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.apmr.2015.04.020","article-title":"Predictors of agitated behavior during inpatient rehabilitation for traumatic brain injury","volume":"96","author":"Bogner","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"2025120619031013000_9.7.e029604.15","doi-asserted-by":"publisher","DOI":"10.3109\/02699052.2012.667587"},{"key":"2025120619031013000_9.7.e029604.16","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9993(92)90003-F"},{"key":"2025120619031013000_9.7.e029604.17","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1016\/j.apmr.2015.01.025","article-title":"Psychotropic Medication Use During Inpatient Rehabilitation for Traumatic Brain Injury","volume":"96","author":"Hammond","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"issue":"Suppl 1","key":"2025120619031013000_9.7.e029604.18","first-page":"P376","article-title":"Pharmacological interventions for agitation in patients with traumatic brain injury","volume":"22","author":"Williamson","year":"2018","journal-title":"Crit Care"},{"key":"2025120619031013000_9.7.e029604.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2008.08.007"},{"key":"2025120619031013000_9.7.e029604.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2008.10.076"},{"key":"2025120619031013000_9.7.e029604.21","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000256722.88854.C0"},{"key":"2025120619031013000_9.7.e029604.22","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2014.3711"},{"key":"2025120619031013000_9.7.e029604.23","article-title":"Pharmacological management for agitation and aggression in people with acquired brain injury","volume":"73","author":"Fleminger","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120619031013000_9.7.e029604.24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rehab.2015.10.003","article-title":"Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice","volume":"59","author":"Plantier","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"2025120619031013000_9.7.e029604.25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02699052.2017.1419377","article-title":"Pharmacological management of agitation among individuals with moderate to severe acquired brain injury: A systematic review","volume":"32","author":"Mehta","year":"2018","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13643-016-0374-6","article-title":"Pharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysis","volume":"5","author":"Williamson","year":"2016","journal-title":"Syst Rev"},{"key":"2025120619031013000_9.7.e029604.27","doi-asserted-by":"publisher","DOI":"10.2174\/1874306400903010123"},{"key":"2025120619031013000_9.7.e029604.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"2025120619031013000_9.7.e029604.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025120619031013000_9.7.e029604.30","unstructured":"Wells G , Shea B , O\u2019Connell D , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013 http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"2025120619031013000_9.7.e029604.31","first-page":"917","article-title":"The treatment of agitation during initial hospitalization after traumatic brain injury","volume":"73","author":"Brooke","year":"1992","journal-title":"Arch Phys Med Rehabil"},{"key":"2025120619031013000_9.7.e029604.32","first-page":"153","article-title":"Effect of methylphenidate on brain injury-related anger","volume":"74","author":"Mooney","year":"1993","journal-title":"Archives of physical medicine and rehabilitation"},{"key":"2025120619031013000_9.7.e029604.33","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.apmr.2010.07.022","article-title":"Article 3 (see Poster 14): Amantadine Hydrochloride for Treatment of Symptoms of the Posttraumatic Confusional State: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"91","author":"Yablon","year":"2010","journal-title":"Arch Phys Med Rehabil"},{"key":"2025120619031013000_9.7.e029604.34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1089\/neu.2014.3803","article-title":"Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study","volume":"32","author":"Hammond","year":"2015","journal-title":"J Neurotrauma"},{"key":"2025120619031013000_9.7.e029604.35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.HTR.0000438116.56228.de","article-title":"Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression","volume":"29","author":"Hammond","year":"2014","journal-title":"J Head Trauma Rehabil"},{"key":"2025120619031013000_9.7.e029604.36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WNF.0000000000000242","article-title":"Effect of Amantadine on Agitation in Critically Ill Patients With Traumatic Brain Injury","volume":"40","author":"Gramish","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"2025120619031013000_9.7.e029604.37","doi-asserted-by":"crossref","unstructured":"Beresford T , Schmidt BK , Buchanan J , et al . A double-blind trial of divalproex sodium for affective lability and ethanol use following traumatic brain injurt. APA abstracts 2015.","DOI":"10.21236\/ADA613323"},{"key":"2025120619031013000_9.7.e029604.38","unstructured":"Maturana Waidele R , Maturana Rodillo R . Control de la agresividad con olanzapina en pacientes post tec \/ Aggressiveness control using olanzapine in post tbi patients Cienc Trab. 2009;31:22\u20134."},{"key":"2025120619031013000_9.7.e029604.39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HTR.0b013e3181d6c715","article-title":"Impact of early administration of sertraline on cognitive and behavioral recovery in the first year after moderate to severe traumatic brain injury","volume":"25","author":"Ba\u00f1os","year":"2010","journal-title":"J Head Trauma Rehabil"},{"key":"2025120619031013000_9.7.e029604.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102609"},{"key":"2025120619031013000_9.7.e029604.41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/026990501750111274","article-title":"Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes","volume":"15","author":"Meythaler","year":"2001","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.42","doi-asserted-by":"publisher","DOI":"10.1080\/026990599121061"},{"key":"2025120619031013000_9.7.e029604.43","doi-asserted-by":"publisher","DOI":"10.1097\/00001199-200208000-00004"},{"key":"2025120619031013000_9.7.e029604.44","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3109\/02699052.2014.930179","article-title":"Traumatic brain injury-related attention deficits: Treatment outcomes with lisdexamfetamine dimesylate (Vyvanse)","volume":"28","author":"Tramontana","year":"2014","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/HTR.0000000000000322","article-title":"Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial","volume":"32","author":"Fann","year":"2017","journal-title":"J Head Trauma Rehabil"},{"key":"2025120619031013000_9.7.e029604.46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/02699052.2013.865267","article-title":"Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain","volume":"28","author":"Johansson","year":"2014","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.47","doi-asserted-by":"crossref","unstructured":"Hart T , Whyte J , Watanabe T , et al . Effects of dextroamphetamine in subacute traumatic brain injury: A randomized, placebo-controlled pilot study. Journal of neuroscience research 2017.","DOI":"10.1002\/jnr.24102"},{"key":"2025120619031013000_9.7.e029604.48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21767\/2471-8505.100023","article-title":"Haloperidol Use in Acute Traumatic Brain Injury: A Safety Analysis","volume":"02","author":"Anderson","year":"2016","journal-title":"J Intensive Crit Care"},{"key":"2025120619031013000_9.7.e029604.49","doi-asserted-by":"publisher","DOI":"10.1080\/02699050600743972"},{"key":"2025120619031013000_9.7.e029604.50","first-page":"30","article-title":"Agitation in closed head injury: haloperidol effects on rehabilitation outcome","volume":"66","author":"Rao","year":"1985","journal-title":"Arch Phys Med Rehabil"},{"key":"2025120619031013000_9.7.e029604.51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.ccm.0000474980.38145.7b","article-title":"1149","volume":"43","author":"Kooda","year":"2015","journal-title":"Crit Care Med"},{"key":"2025120619031013000_9.7.e029604.52","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"2025120619031013000_9.7.e029604.53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0033-3182(89)72297-0","article-title":"Treatment of Behavioral Problems with Pindolol","volume":"30","author":"Greendyke","year":"1989","journal-title":"Psychosomatics"},{"key":"2025120619031013000_9.7.e029604.54","first-page":"423","article-title":"Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study","volume":"47","author":"Greendyke","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"2025120619031013000_9.7.e029604.55","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198605000-00005"},{"key":"2025120619031013000_9.7.e029604.56","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/HTR.0000000000000342","article-title":"Potential Impact of Amantadine on Aggression in Chronic Traumatic Brain Injury","volume":"32","author":"Hammond","year":"2017","journal-title":"J Head Trauma Rehabil"},{"key":"2025120619031013000_9.7.e029604.57","unstructured":"Aquired Brain Injury Knowledge Uptake Strategy (ABIKUS) guideline development group. Evidence based recommendations for rehabilitation of moderate to severe acquired brain injury. 2007 http:\/\/www.abiebr.com\/pdf\/abikus_aug_07.pdf."},{"key":"2025120619031013000_9.7.e029604.58","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.18.4.547"},{"key":"2025120619031013000_9.7.e029604.59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/026990501458399","article-title":"Methotrimeprazine in the treatment of agitation in acquired brain injury patients","volume":"15","author":"Maryniak","year":"2001","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.60","doi-asserted-by":"publisher","DOI":"10.1080\/026990500120736"},{"key":"2025120619031013000_9.7.e029604.61","doi-asserted-by":"publisher","DOI":"10.1097\/01.PHM.0000091982.33232.CB"},{"key":"2025120619031013000_9.7.e029604.62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HTR.0000000000000074","article-title":"INCOG recommendations for management of cognition following traumatic brain injury, part I: posttraumatic amnesia\/delirium","volume":"29","author":"Ponsford","year":"2014","journal-title":"J Head Trauma Rehabil"},{"key":"2025120619031013000_9.7.e029604.63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/02699052.2014.992474","article-title":"Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: A cross-sectional survey","volume":"29","author":"Pisa","year":"2015","journal-title":"Brain Inj"},{"key":"2025120619031013000_9.7.e029604.64","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9993(97)90051-4"},{"issue":"Suppl 1","key":"2025120619031013000_9.7.e029604.65","first-page":"P219","article-title":"Agitation after mild to moderate traumatic brain injury in the intensive care unit","volume":"21","author":"Perreault","year":"2017","journal-title":"Crit Care"},{"key":"2025120619031013000_9.7.e029604.66","doi-asserted-by":"publisher","DOI":"10.1682\/JRRD.2008.09.0120"},{"key":"2025120619031013000_9.7.e029604.67","doi-asserted-by":"publisher","DOI":"10.1080\/0269905031000110463"},{"key":"2025120619031013000_9.7.e029604.68","doi-asserted-by":"publisher","DOI":"10.1080\/026990599121188"},{"key":"2025120619031013000_9.7.e029604.69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/jnp.12.3.395","article-title":"Agitated symptom response to divalproex following acute brain injury","volume":"12","author":"Chatham Showalter","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2025120619031013000_9.7.e029604.70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1176\/jnp.8.1.96","article-title":"Carbamazepine for combativeness in acute traumatic brain injury","volume":"8","author":"Chatham-Showalter","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2025120619031013000_9.7.e029604.71","doi-asserted-by":"publisher","DOI":"10.1080\/026990597123791"},{"key":"2025120619031013000_9.7.e029604.72","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.14.2.202"},{"key":"2025120619031013000_9.7.e029604.73","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-13-177","article-title":"Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial","volume":"13","author":"Patel","year":"2012","journal-title":"Trials"},{"key":"2025120619031013000_9.7.e029604.74","doi-asserted-by":"publisher","DOI":"10.1080\/01688638908400888"},{"key":"2025120619031013000_9.7.e029604.75","doi-asserted-by":"publisher","DOI":"10.1177\/088626087002002003"},{"key":"2025120619031013000_9.7.e029604.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2004.09.029"},{"key":"2025120619031013000_9.7.e029604.77","first-page":"6","article-title":"The functional independence measure: a new tool for rehabilitation","volume":"1","author":"Keith","year":"1987","journal-title":"Adv Clin Rehabil"},{"key":"2025120619031013000_9.7.e029604.78","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"2025120619031013000_9.7.e029604.79","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1963.13.2.503"},{"key":"2025120619031013000_9.7.e029604.80","doi-asserted-by":"crossref","unstructured":"Kreutzer J , Seel R , Marwitz J . The Neurobehavioral Functioning Inventory.: The Psychological Corporation. San Antonio, TX, 1999.","DOI":"10.1037\/t15126-000"},{"key":"2025120619031013000_9.7.e029604.81","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.50.2.183"},{"key":"2025120619031013000_9.7.e029604.82","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.1.35"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-029604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:03:27Z","timestamp":1765076607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-029604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,9]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bmjopen-2019-029604"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-029604","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}